AstraZeneca to Invest $1.77 Billion in CSPC's siRNA Platform for Novel Kidney Drug Discovery
AstraZeneca is partnering with China's CSPC Pharmaceutical Group to develop novel RNA interference (siRNA) therapeutics targeting extrahepatic organs. The collaboration focuses on jointly discovering candidate molecules for two undisclosed kidney disease targets, leveraging CSPC's AI-driven molecular design and automated high-throughput screening systems. This initiative reflects AstraZeneca's commitment to securing a proprietary platform technology capable of precisely delivering drugs to extrahepatic organs, overcoming the limitations of conventional siRNA therapies that primarily accumulate in the liver. By expanding the application of RNA therapeutics beyond liver diseases to chronic kidney disease, AstraZeneca aims to address significant unmet medical needs.
The agreement includes an upfront payment of $30 million, with development milestones totaling $540 million and sales milestones of up to $1.2 billion, for a total potential value of $1.77 billion. AstraZeneca will have the option to acquire exclusive global rights or worldwide rights to the resulting candidates, while CSPC will retain exclusive rights to at least one asset in China, creating a balanced risk-sharing and market-partitioning structure.
AstraZeneca already possesses a strong portfolio of blockbuster kidney drugs, and this preclinical siRNA pipeline is expected to create significant synergies. Farxiga (dapagliflozin), an SGLT2 inhibitor approved for chronic kidney disease and diabetes, generated $2.2 billion in revenue in the first quarter of 2026, making it the company's top revenue driver. Lokelma (sodium zirconium cyclosilicate), a treatment for hyperkalemia, also contributed significantly with $199 million in revenue during the same period, further strengthening AstraZeneca's renal lineup. This siRNA collaboration represents an expansion of AstraZeneca's portfolio beyond small molecule compounds and potassium binders to include next-generation gene therapies, solidifying its leading position in the kidney disease market.
The kidney disease therapeutics market is rapidly growing, with an estimated value of $15 billion to $17 billion by 2026, but there is a lack of targeted therapies. The competition to deliver siRNA to cells outside the liver is fierce, with companies like Judo Bio and Rigerna also developing competing platforms. SanegeneBio's recent IND approval for SGB-3383, a CFB-targeting siRNA, signals the beginning of a new era of RNA therapeutics for kidney diseases. In addition to the CSPC collaboration, AstraZeneca has also entered into multiple partnerships with Chinese biotech companies, leveraging their rapid R&D capabilities and AstraZeneca's commercialization expertise.
AstraZeneca is strengthening its leading position in the $15 billion to $17 billion chronic kidney disease (CKD) market by proactively securing a preclinical-stage extrahepatic siRNA delivery platform technology. In the short term, the company is investing $30 million upfront to secure two target siRNA candidates, and in the long term, it is hedging its risk with a structure that includes development and sales milestones totaling up to $1.77 billion. This deal is a portfolio diversification strategy to prepare for the patent expiration of Farxiga and a strategic response to competing kidney-targeted pipelines from companies like Judo Bio and SanegeneBio. From a research and industry perspective, this collaboration is seen as a technological demonstration of overcoming the long-standing challenge of efficient extrahepatic delivery, expanding the therapeutic target of RNA therapeutics from the liver to kidney tissues.